CSRXP LAUNCHES SIX-FIGURE ADVERTISING CAMPAIGN TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTICOMPETITIVE PRACTICES AND EGREGIOUS DRUG PRICING

Campaign Spoofs Big Pharma’s Direct-to-Consumer (DTC) Ads While Highlighting Their Patent Abuse and Price Gouging Practices That Keep Prescription Drug Prices High

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) announced the launch of a new six-figure advertising campaign Monday highlighting how Big Pharma’s pricing practices, anti-competitive tactics and massive spending on direct-to-consumer (DTC) advertising are the root cause of high prescription drug prices in America.

“CSRxP’s new campaign invokes Big Pharma’s own imagery to highlight how the pharmaceutical industry games the system to block competition, keep drug prices high and increase sales of high-priced blockbuster products by spending billions of dollars each year on advertising directly targeting consumers,” said CSRxP executive director Lauren Aronson. “Congress and the Administration should act on growing bipartisan support for holding Big Pharma accountable for patent abuse and aggressive marketing practices that undermine competition from more affordable alternatives, keep drug prices high and cost the American people billions of dollars each year.”

The campaign follows the recent release of a report conducted by CSRxP which found Big Pharma’s DTC ad spending costs U.S. taxpayers billions of dollars each year, due to the combined impact of increasing utilization and the pharmaceutical industry’s practice of writing off marketing expenses from business taxes, to further pad their bottom line.

CSRxP’s campaign will start with a two-month, six-figure flight of video and display advertising in Washington, D.C. See the ads here:

Watch the ad “Max Profitrexil” HERE.

Watch the ad “Patent Abuserol” HERE.

Read CSRxP’s recent report on the cost of Big Pharma’s DTC advertising HERE.

Read more on bipartisan, market-based solutions to lower drug prices by holding Big Pharma accountable for anti-competitive abuse of the U.S. patent system HERE.

Read more on additional bipartisan, market-based solutions to hold Big Pharma accountable HERE.